Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
Open Access
- 12 March 2010
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 149 (4), 537-549
- https://doi.org/10.1111/j.1365-2141.2010.08127.x
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf–mediated interactions with bone marrow stromal cellsPublished by American Society of Hematology ,2009
- β1 Integrin Adhesion Enhances IL-6–Mediated STAT3 Signaling in Myeloma Cells: Implications for Microenvironment Influence on Tumor Survival and ProliferationCancer Research, 2009
- CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsOncogene, 2008
- Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieuBlood, 2008
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced CancersJournal of Clinical Oncology, 2008
- Preclinicalversusclinical drug combination studiesLeukemia & Lymphoma, 2008
- Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisBlood, 2007
- Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistanceBlood, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002